Novartis Pharma B.V.

Location

Noord-Holland

Founded

1948-02-10

Risk Signals

21161 news mentions monitored

Industry Context

This company is tracked across risk categories, including those related to its sector (e.g., Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.

Recent Articles about Novartis Pharma B.V.

Live alerts from global media, monitored by Business Radar

Sentiment on the stock market is mixed: the stock market is languishing

2024-02-10 (rheintaler.ch)

Sentiment on the stock market is mixed: the stock market is languishing

While the US stock exchanges continue their hunt for records, the Swiss stock market is languishing. The annual financial statements are mixed.

Read more
Physicians Financial Services Inc. Decreases Stock Position in Novartis AG (NYSE:NVS)

2023-09-13 (defenseworld.net)

Physicians Financial Services Inc. Decreases Stock Position in Novartis AG (NYSE:NVS)

Physicians Financial Services Inc. cut its position in Novartis AG (NYSE:NVS – Free Report) by 0.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission.

Read more
Dynamic Advisor Solutions LLC Sells 645 Shares of Novartis AG (NYSE:NVS)

2023-03-26 (defenseworld.net)

Dynamic Advisor Solutions LLC Sells 645 Shares of Novartis AG (NYSE:NVS)

Dynamic Advisor Solutions LLC lowered its stake in shares of Novartis AG (NYSE:NVS – Get Rating) by 13.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC).

Read more
North Star Investment Management Corp. Sells 598 Shares of Novartis AG (NYSE:NVS)

2023-03-22 (defenseworld.net)

North Star Investment Management Corp. Sells 598 Shares of Novartis AG (NYSE:NVS)

North Star Investment Management Corp. cut its holdings in Novartis AG (NYSE:NVS – Get Rating) by 30.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).

Read more
Novartis Hellas S.A.C.I. and Alcon Pte Ltd Agree to Pay over $233 Million Combined to Resolve Criminal FCPA Cases

2020-06-25 (justice.gov)

Novartis Hellas S.A.C.I. and Alcon Pte Ltd Agree to Pay over $233 Million Combined to Resolve Criminal FCPA Cases

Novartis Hellas S.A.C.I. ( Novartis Greece), a subsidiary of Novartis AG, a Switzerland-based global pharmaceutical company, and Alcon Pte Ltd, a former subsidiary of Novartis AG and current subsidiary of Alcon Inc., a multinational eye care company, have agreed to pay a combined total of more than$

Read more
Compare Novartis with Peers on Key Fundamentals and Financials - NDTV

2019-08-26 (ndtv.com)

Compare Novartis with Peers on Key Fundamentals and Financials - NDTV

Peers Comparison page helps you compare Novartis with its sector peers on key fundamentals, financial statements and yearly results. To find out how the performance measures up with its peers select the companies that you want to compare and click

Read more
Novartis Pharma AG: Sandoz publishes supplement to the listing prospectus, including Sandoz's financial statements for the first half of 2023

(finanznachrichten.de)

Novartis Pharma AG: Sandoz publishes supplement to the listing prospectus, including Sandoz's financial statements for the first half of 2023

Ad hoc announcement in accordance with Art. 53 LR Supplement from Sandoz published before the Extraordinary General Meeting of Novartis on September 15, 2023The results of the first half of the year showed a

Read more
Novartis Pharma AG: Sandoz publishes supplement to the listing prospectus, including Sandoz's financial statements for the first half of 2023

(finanznachrichten.de)

Novartis Pharma AG: Sandoz publishes supplement to the listing prospectus, including Sandoz's financial statements for the first half of 2023

Ad hoc announcement in accordance with Art. 53 LR Supplement from Sandoz published before the Extraordinary General Meeting of Novartis on September 15, 2023The results of the first half of the year showed a

Read more
EQS-GM: MorphoSys AG: Announcement of the convening of the Annual General Meeting on May 17, 2023 in Planegg with the aim of disseminating it throughout Europe in accordance with Section 121 AktG (10619172) - April 4, 2023 - News - ARIVA.DE

(ariva.de)

EQS-GM: MorphoSys AG: Announcement of the convening of the Annual General Meeting on May 17, 2023 in Planegg with the aim of disseminating it throughout Europe in accordance with Section 121 AktG (10619172) - April 4, 2023 - News - ARIVA.DE

Message: EQS-GM: MorphoSys AG: Announcement of the convening of the Annual General Meeting on May 17, 2023 in Planegg with the aim of disseminating it throughout Europe in accordance with Section 121 AktG (10619172) - April 4, 2023 - News

Read more

Never miss a headline about Novartis Pharma B.V.

Set up smart alerts with Business Radar and receive real-time updates on any new risk signal or major news story.

  • ✔️ Used by 100+ compliance teams and analysts
  • ✔️ Covers 154M+ sources in 40+ languages